

(3)

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number  
**WO 2004/087031 A1**

(51) International Patent Classification<sup>7</sup>: A61G 13/00,  
A61B 6/04, C09D 183/04

MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/IB2004/050348

(22) International Filing Date: 26 March 2004 (26.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

(30) Priority Data:  
03100836.0 31 March 2003 (31.03.2003) EP

## Declaration under Rule 4.17:

(71) Applicant (for all designated States except US): KONIN-  
KLJKE PHILIPS ELECTRONICS N.V. [NL/NL];  
Groenewoudseweg 1, NL-5621 BA Eindhoven (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KOLE, Henk  
[NL/NL]; c/o Prof. Holstlaan 6, NL-5656 AA Eindhoven  
(NL). BOUWKAMP-WIJNOLTZ, Anna, L. [NL/NL];  
c/o Prof. Holstlaan 6, NL-5656 AA Eindhoven (NL).  
LEGIERSE, Petrus, E., J. [NL/NL]; c/o Prof. Holstlaan  
6, NL-5656 AA Eindhoven (NL). VISSER, Cornelis, G.  
[NL/NL]; c/o Prof. Holstlaan 6, NL-5656 AA Eindhoven  
(NL). BOEHMER, Marcel, R. [NL/NL]; c/o Prof. Holst-  
laan 6, NL-5656 AA Eindhoven (NL).

(74) Agent: COHEN, Julius, S.; Prof. Holstlaan 6, NL-5656  
AA Eindhoven (NL).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,  
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,  
LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG)

## Published:

— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: MEDICAL EQUIPMENT PROVIDED WITH A COATING

(57) Abstract: Disclosed is medical equipment, the surface of which being at least partially provided with a coating which is pro-  
vided by means of a sol-gel process. By applying such coating staining of the medical equipment by iodine-containing agents is  
prevented. The sol-gel coating can be cured at a curing temperature of 80°C or lower. The medical equipment can, for example,  
comprise a tabletop of a diagnostic system.

WO 2004/087031 A1

## Medical equipment provided with a coating

The invention relates to medical equipment that is at least provided with a coating.

Medical equipment, such as for example a tabletop of a diagnostic system, is frequently exposed to chemical compounds such as iodine-containing agents. Said compounds often cause staining of the surface of the equipment, thereby deteriorating the appearance thereof.

In Japanese patent application JP 01-259845 a coated tabletop of a medical table for accommodating a patient has been described. The tabletop is coated with a urethane film to generate no X-ray transmission characteristics and virtual image, to suppress slip, and to hold beautiful appearance. It is further described that the film has good releasability to almost all of the chemicals used in medical treatment. However, it was found that the resistance against iodine-containing agents is poor. It was found that spilled iodine, for instance from iodine-containing contrast solutions, penetrates the urethane film, giving iodine stains that cannot be removed. The appearance of the film thereby strongly decreases. It is an object of the invention to provide medical equipment that is much more resistant against, for example, iodine stains, and nevertheless maintains the above other advantageous properties.

To this end, the present invention provides for medical equipment, the surface of which being at least partially provided with a coating which is provided by means of a sol-gel process.

It is noted that sol-gel coatings (or lacquers) per se are known in the art. In PCT patent application WO 98/13434 products for personal care, particularly electric shavers, are provided with a coating that contain a network of a hydrolytically condensed organosilane compound. This coating is provided to the shaver to protect it against compositions for personal care, such as cosmetics, lotions, shampoos and other skin-care products, particularly shaving lotions, such as pre-shaves and aftershaves, which are found to be aggressive relative to other coatings. However, the advantageous properties of such coatings for use in medical equipment for preventing iodine staining are not disclosed.

Advantageously, the sol-gel process at least comprises the step of mixing together an organosilane compound and water.

JC20 Rec'd PCT/PTO 27 SEP 2005

Preferably, the sol-gel process at least comprises the step of mixing together an organosilane compound and silica particles.

The coating materials according to the present invention are known as materials obtained by means of a sol-gel process or, if they are combined by means of organic polymers, as hybrid or composite materials, heteropolysiloxanes, ormocers, or ormosils. However, these materials are not understood to be siloxanes formed from linear chains or silicone rubbers derived from said siloxanes or other inorganic polymers having a low cross-link density. Preferably, the coating is made of a hydrolytically condensed organosilane sol-gel composition. An organosilane compound or a substituent contained therein is considered to be hydrolytically condensable when the compound contains a silanol group, -Si-OH, or when a silanol group can be formed from said compound by using water, and two silanol groups can react to form an Si-O-Si bond while eliminating water. When these reactions have (partially) taken place, then the compound is (partially) hydrolytically condensed. If the organosilane compound comprises three or more hydrolytically condensable substituents, a network can be formed by hydrolytic condensation. If the above-mentioned substituents are linked to one silicon atom, then said silicon atom serves as the cross-link. This and other information on sol-gels is known in the art, for example from B. M. Novak in Adv. Mat., 5(6), 1993, p. 422, or H. Schmidt in J. Non-Cryst. Sol. 73, 1985, p. 681, and J. Non-Cryst. Sol. 121, 1990, p. 428.

Suitable hydrolytically condensable organosilane compounds are compounds in accordance with the formula  $\text{SiX}_p\text{Y}_q\text{Z}_r$ , wherein X is a hydrolytically condensable substituent selected, for example, from the group formed by halogen, hydroxy, alkoxy, acyloxy or amino, Y is a polymerizable substituent R-A, wherein R is an alkylene or arylalkylene, possibly interrupted by an oxygen atom or a sulfur atom, or an NH-group, and the substituent A is selected, for example, from the group formed by halogen, amino, amide, aldehyde, alkylcarbonyl, carboxy, thio, cyano, alkoxy, alkoxycarbonyl, sulfonic acid, phosphoric acid, acryloxy, methacryloxy, epoxy or vinyl, and Z is a hydrolytically non-condensable and non-polymerizable substituent which is selected, for example, from the group formed by alkyl and aryl, wherein p is equal to 2, 3, or 4, q is equal to 0, 1, or 2, r is equal to 0 or 1, p+q is greater than 2 and p+q+r is equal to 4. Each time X, Y, or Z occurs, it is possible, of course, to make a new choice from the above-mentioned groups. Coatings are preferably prepared from mixtures of the above-mentioned organosilane compounds.

In a suitable method of processing said organosilane compounds, an approximately stoichiometric quantity of water is added, so that the hydrolytically

condensable substituents are hydrolyzed, thereby forming -Si-OH groups, which while eliminating water, condense to form Si-O-Si bonds. If necessary, said processing step can be carried out in a solvent, and, preferably, an acid, such as hydrochloric acid, or a base, such as caustic soda, is used as a catalyst. Polymerization of the polymerizable substituents by means  
5 of radical-polymerization or condensation-polymerization takes place in ways known to those skilled in the art.

A coating can be obtained, for example, by partly hydrolytically condensing an organosilane compound at room temperature, thereby forming a sol, which sol is subsequently provided on a substrate by means of, for example spin-coating, after which the  
10 hydrolytic condensation is completed by curing the coating at an elevated temperature, thereby forming the network.

In an preferred embodiment, the organosilane compound comprises tetraethoxysilane (TEOS).

Coatings which are prepared from organosilane compounds containing four  
15 hydrolytically condensable substituents, such as tetraethyl orthosilicate, exhibit a good resistance to iodine-containing compositions. In order to obtain a high cross-link density, without the coating exhibiting cracks, glycidoxypentyl trimethoxysilane (GLYMO) is preferably also used as an organosilane compound.

In order to further avoid the development of cracks, particularly if the coatings  
20 are thicker than approximately 500 nm, the organosilane compound preferably comprises methyltrimethoxysilane (MTMS).

In a preferred coating material at least one substituent of the organosilane compound is not hydrolytically condensable. In terms of the formula  $\text{SiX}_p\text{Y}_q\text{Z}_r$ , this means that p is chosen to be in the range of 2.0 to 4.0. Because of the resistance to emollients, p is  
25 preferably in the range of 3.0 to 3.5. Suitable organosilane compounds are, for example, alkyl trialkoxysilanes, such as methyl trimethoxysilane, methyl triethoxysilane, ethyl trimethoxysilane, ethyl triethoxysilane, tetraethoxysilane. Phenyl trimethoxysilane and epoxy-silane derivatives such as glycidoxypentyl trimethoxysilane are suitable too. These organosilane compounds can be used alone or in mixtures to form coatings having a  
30 thickness of at least 10 micrometers, and, if desirable, dyes, pigments or other fillers, such as silica particles, dispersions, or soot, may be added to said coatings.

It is preferred that the organosilane compound contains an organic, polymerizable substituent. The use of an organic, polymerizable substituent enables a high cross-link density to be achieved, without the coating exhibiting cracks, so that a very good

resistance to emollients is achieved. In terms of the formula  $\text{SiX}_p\text{Y}_q\text{Z}_r$ , in this case,  $q$  is equal to 1 or 2. Preferably,  $q$  is equal to 1. Suitable organosilane compounds are epoxides, such as 3-glycidoxypyrpyl trimethoxysilane (GLYMO), by means of which a polyether chain between silicon atoms can be realized, (meth)acrylates, such as methacryloxypyrpyl trimethoxysilane, or vinylsilanes, such as vinyl trimethoxysilane.

The coating may also contain inorganic or organic pigments, photocatalytic pigments and dyes in all available colors, including coated and non-coated aluminum pigments and (optical) interference and view-angle dependant multicolor pigments.

The coatings may be glossy or may have a matt appearance. If a matted coating is preferred, a matting agent as known in the art may be added to the composition.

Preferably, the coating has been cured at a curing temperature of 80°C or lower.

It is preferred to use sol-gels that can be cured at a curing temperature of 80°C or lower, particularly when applied on tabletops of medical equipment. It is noted that the coatings of the prior art have curing temperatures of 130°C or higher, which supersede the maximum temperature impact of 80°C for such tabletops, above which a loss of mechanical (loading) strength is observed. The sol-gel compositions according to this invention have a curing temperature of 80°C or lower. It is stressed that UV curable sol-gel compositions are encompassed in this definition, as long as the UV curing is performed at 80°C or lower. It will, however, be clear to the skilled person that while the sol-gels according to the present invention can be cured at 80°C, curing at higher temperatures, if required, can also take place.

Sol-gels that can be cured at about or below 80°C and that do not affect in a negative way the mechanical strength of substrates like tabletops of medical and diagnostic systems, may, for instance, be made of mixtures of tetraethoxysilane, glycidoxypyrpyl trimethoxysilane, and silica dispersion. These coatings proved to be resistant to a solution of 1 wt.% iodine in 70 wt.% ethanol for at least 3 hours. It goes further without saying that the coating should satisfy the other normal requirements for medical equipment, such as biocompatibility, resistance against X-radiation, disinfectants, and cleaning agents, and the like.

In a preferred embodiment of the invention an acid is added during the sol-gel process for making the coating, which acid is chosen from the group comprising malonic acid, dimethylmalonic acid and itaconic acid.

By adding an acid from the above group during the sol-gel process a crack and stain free sol-gel layer can be obtained.

The invention in particular relates to medical equipment, which is at least partially provided with a coating of said sol-gel composition, i.e. at parts that can come in contact with iodine-containing agents. The invention is particularly useful for tabletops of diagnostic systems that can come easily in contact with iodine-containing solutions, such as contrast solutions, medical cleaning solutions, disinfectants, and the like.

It was found that sol-gel hybrid coatings, as described hereinbefore, have further high mechanical, chemical, and heat resistance.

The invention is further illustrated by the following non-limitative examples.

10 Example 1

A composition for a glossy iodine-resistant coating was made, containing:

- 28.4 g of demi-water
- 2.8 g of itaconic acid (methylenesuccinic acid) (ex Merck)
- 9.0 g of ethyl alcohol
- 15 29.3 g of tetraethoxysilane (TEOS)
- 20.4 g of glycidoxypropyl trimethoxysilane (GLYMO)
- 72.8 g of silica dispersion (Ludox® TMA; ex Aldrich)
- 1.1 g of wetting agent (Tegowet® 280; ex Tego Chemie)

20 14.2 g of demi-water was brought into a beaker and 9.1 g of Ludox® TMA were added and the mixture was stirred for 2 hours or until a nice dispersion without clogged particles was formed. The beaker was closed and this pre-mix was put aside.

In another beaker, 14.2 g of demi-water, 9.0 g of ethyl alcohol and 2.8 g of itaconic acid were added and stirred until the acid was completely dissolved.

25 Under stirring 29.3 g of TEOS were added followed by 20.4 g of GLYMO and the mixture was stirring for 45 minutes.

After 45 minutes the pre-mix was added slowly under stirring and stirring was maintained for 5 minutes. Thereafter 1.1 g of Tegowet 280 were added slowly under stirring and stirring was maintained for 5 minutes. After 5 minutes the beaker with the mixture was closed, and very slowly stirred or just put aside for at least 24 hours to bring the hydrolization reaction to completion, after which the mixture was ready for use for application by spraying, dipping, dispensing, or any other application methods for wet compositions.

The pot-life of the mixture was at least 3 days.

Example 2

A composition for a matted iodine-resistant coating was made, containing:

- 28.4 g of demi-water  
g of itaconic acid (methylenesuccinic acid)(ex Merck)  
5 g of ethyl alcohol  
29.3 g of tetraethoxysilane (TEOS)  
20.4 g of glycidoxypopyl trimethoxysilane (GLYMO)  
72.8 g of silica dispersion (Ludox® TMA; ex Aldrich)  
3.0 g of matting agent (Syloid® ED 30; ex Grace)  
10 1.1 g of wetting agent (Tegowet® 280; ex Tego Chemie)

- The composition was made according to Example 1, with Syloid ED 30 added slowly step by step to the Ludox® TMA/demi-water mixture while stirring (3.0 g in total) and stirring was maintained for 2 hours or until a nice dispersion without clogged particles  
15 was formed.

Example 3

Surface contact-test

- 20 Procedure:

- A tissue, which was free from wood fiber, was soaked into a 70 wt.% iodine solution in ethyl alcohol and was put onto a surface for testing, which was coated with various coating (see Table). The soaked tissue was shielded mainly from the open air by placing a plastic beaker with a small hole (diameter about 1 – 2 mm) in the bottom thereof  
25 upside down over the tissue.

The maximum contact time in hours for which discoloration did not occur, was determined by visual inspection. A contact time of at least 24 h is required to be classified as sufficiently iodine staining proof.

- 30 Results with different coating types:

Table

Entry	Coating type	Contact time
-------	--------------	--------------

		in h
1	two-component poly-urethane solvent borne, curing at 80°C, Dualux™ / VM01, ex: Akzo Nobel (Sassenheim, NL)	<1
2	two-component poly-urethane waterborne, curing at 80°C, Formulation M-400, ex: Neoresins (Waalwijk, NL)	<1
3	two-component epoxide, curing at 80°C, Sigma CM/CM, ex: Sigma Coatings (Uithoorn, NL)	<1
4	special purpose epoxy polysiloxane hybrid, anti graffiti coating, curing at 20 °C, PSX 700 / Amercoat 4093, ex: Ameron Int. (Geldermalsen, NL)	<1
5	sol-gel hybrid, silica type, curing at 80°C, MP-100, ex SDC Coatings (GB)	>3
6	sol-gel hybrid, silica type, UV curing at 20°C, Desolite 4D5-15, ex DSM Desotech (USA)	>3
7	sol-gel hybrid, silica type, curing at 80°C (composition of Example 1)	>3
8	sol-gel hybrid, silica type, curing at 80°C (composition of Example 2)	>3



## CLAIMS:

1. Medical equipment, the surface of which being at least partially provided with a coating which is provided by means of a sol-gel process.
2. Medical equipment according to claim 1, characterized in that the sol-gel  
5 process at least comprises the step of mixing together an organosilane compound and water.
3. Medical equipment according to claim 1, characterized in that the sol-gel process at least comprises the step of mixing together an organosilane compound and silica particles.  
10
4. Medical equipment according to claim 2 or 3, characterized in that the organosilane compound comprises tetraethoxysilane (TEOS).
5. Medical equipment according to claim 1, characterized in that the coating can  
15 be cured at a curing temperature of about 80°C or lower.
6. Medical equipment according to claim 1, characterized in that during the sol-gel process for making the coating an acid is added, which acid is chosen from the group comprising malonic acid, dimethylmalonoc acid and itaconic acid.  
20
7. The medical equipment of any one of claims 1-5 wherein the equipment is a tabletop of a diagnostic system.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB2004/050348

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 A61G13/00 A61B6/04 C09D183/04		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61G A61B C09D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, PAJ, WPI Data		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 291 070 B1 (MUELLER PETER ET AL) 18 September 2001 (2001-09-18) column 1, line 39 - column 2, line 49 column 3, line 45 - column 6, line 27 column 9, lines 8-34 column 10, lines 28-34; claim 12; examples	1-7
X	WO 02/36701 A (INST NEUE MAT GEMEIN GMBH ; URSAPHARM ARZNEIMITTEL GMBH & (DE); BUXMAN) 10 May 2002 (2002-05-10) page 2, lines 7-25 page 3, lines 11-18 page 4, line 1 - page 9, line 19 page 12, line 11 - page 13, line 13 page 15, lines 5-10 page 17, lines 16-21 ----- -/--	1-7
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family		
Date of the actual completion of the international search 29 July 2004		Date of mailing of the international search report 05/08/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Maremonti, M

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB2004/050348

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 501 055 A (ARMSTRONG WORLD IND INC) 2 September 1992 (1992-09-02) page 2, line 45 - page 4, line 15 page 4, lines 45-50 page 6, lines 35-46 page 7, line 5 - page 10, line 15	1-7
X	PATENT ABSTRACTS OF JAPAN vol. 0134, no. 72 (C-647), 25 October 1989 (1989-10-25) & JP 1 185262 A (TOSHIBA CORP), 24 July 1989 (1989-07-24) abstract	1,7
A	US 2001/032568 A1 (SCHUTT JOHN B) 25 October 2001 (2001-10-25) paragraphs '0003!, '0039! - '0049!, '0083!, '0085!, '0136!; examples 1,10	1-7

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB2004/050348

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6291070	B1	18-09-2001	DE 19719948 A1	19-11-1998
			DE 19746885 A1	24-06-1999
			AU 7654598 A	08-12-1998
			WO 9851747 A1	19-11-1998
			EP 0981583 A1	01-03-2000
			JP 2001526719 T	18-12-2001
			TR 9902788 T2	21-02-2000
WO 0236701	A	10-05-2002	DE 10054248 A1	08-05-2002
			AU 7640501 A	15-05-2002
			WO 0236701 A1	10-05-2002
			EP 1330501 A1	30-07-2003
			JP 2004512940 T	30-04-2004
			US 2004029834 A1	12-02-2004
EP 0501055	A	02-09-1992	US 5023140 A	11-06-1991
			CA 1318441 C	25-05-1993
			EP 0501055 A1	02-09-1992
			US 5120811 A	09-06-1992
JP 1185262	A	24-07-1989	NONE	
US 2001032568	A1	25-10-2001	AU 5167901 A	12-09-2001
			AU 774200 B2	17-06-2004
			AU 5168001 A	20-08-2001
			BR 0108763 A	03-12-2002
			CA 2373609 A1	16-08-2001
			CA 2401572 A1	07-09-2001
			CN 1430537 T	16-07-2003
			CN 1425049 T	18-06-2003
			EP 1268696 A1	02-01-2003
			EP 1257367 A2	20-11-2002
			JP 2003531924 T	28-10-2003
			NO 20024084 A	28-10-2002
			NZ 515377 A	30-04-2004
			WO 0164804 A1	07-09-2001
			WO 0158972 A2	16-08-2001
			US 2002102417 A1	01-08-2002
			US 2001030038 A1	18-10-2001
			BR 0108765 A	30-09-2003
			CA 2408892 A1	28-08-2001
			CN 1486354 T	31-03-2004
			EP 1311250 A2	21-05-2003
			WO 02100151 A2	19-12-2002
			US 2001056141 A1	27-12-2001
			ZA 200207763 A	21-01-2004